Published in Fitness and Wellness Business Week, June 28th, 2006
Study 1: Review discusses endocannabinoids and the cannabinoid type 1 receptor (CB1) in the control of energy balance.
According to a recent review from Italy, "The promising results obtained by clinical trials using Rimonabant to tackle visceral obesity and related disorders recently promoted a remarkable impulse to carry out detailed investigations into the mechanisms of action of endocannabinoids in regulating food intake and energy metabolism. The endocannabinoid system has been known for many years to play an important role in the modulation of the neuronal pathways...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Fitness and Wellness Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.